StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

COSMBullishcompany_operating_resultsnews
High materiality7/10

Cosmos Health Reports Record Nine-Month Revenue of $53.6 Million, Up 18%; Q3 Gross Margin Up 465 Basis Points Sequentially; Total Debt Down 34% and Stockholders' Equity Up 21% Since Year-End

Nov 18, 2026, 9:31 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

The results show revenue growth and margin recovery (revenue mechanism) alongside a materially stronger balance sheet after the ATW note settlement (improves cash-flow/financing flexibility). Continued subscription and contract-manufacturing momentum could support longer-term revenue, but near-term non-cash charges still drive GAAP losses.

AI summary

What happened, with direct paths to the underlying reporting

Cosmos Health reported record nine-month revenue of $53.59M (up 17.6%), sequential gross-margin improvement to 12.6%, and a 33.8% reduction in total debt driven by early settlement of an $8.0M convertible note; contract-manufacturing backlog exceeded 32.7M units.

  • Nine-month revenue reached $53.59 million, up 17.6% from $45.57 million in the first nine months of 2025.
  • Q3 gross margin rebounded to 12.6%, up 465 basis points from 7.96% in Q2 2026.
  • Total debt declined 33.8% to $12.83 million year-to-date, primarily reflecting the full settlement of the $8.0 million ATW convertible note.
  • Cana Laboratories' contract manufacturing pipeline grew to a record of more than 32.7 million units, representing over $20 million in implied revenue and over $18 million in implied gross profit.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.